Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.47 |
| ▸ | NEK2 | P51955 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | KIF20A | O95235 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857593 | 0.85 | MAP2K1 (0.55) | MAP2K1CNR2CAMKK2NEK2DYRK1A | |
| SCHEMBL12646997 | 0.85 | MAP2K1 (0.58) | MAP2K1CNR2CAMKK2NEK2DYRK1A | |
| SCHEMBL1266725 | 0.84 | MAP2K1 (0.53) | MAP2K1CNR2CAMKK2NEK2DYRK1A | |
| SCHEMBL878925 | 0.83 | KIF20A (0.59) | MAP2K1CNR2CAMKK2NEK2DYRK1A | |
| SCHEMBL24011615 | 0.82 | MAP2K1 (0.53) | MAP2K1CNR2CAMKK2NEK2DYRK1A | |
| SCHEMBL27708260 | 0.81 | MAP2K1 (0.71) | MAP2K1CNR2CAMKK2NEK2DYRK1A | |
| SCHEMBL697424 | 0.81 | GPR84 (0.59) | GPR84SMN1; SMN2NAPRTKMT2A | |
| SCHEMBL12772764 | 0.81 | MAP2K1 (0.58) | MAP2K1CNR2CAMKK2NEK2DYRK1A | |
| SCHEMBL878719 | 0.80 | MAP2K1 (0.61) | MAP2K1CNR2CAMKK2NEK2KDR | |
| SCHEMBL2984625 | 0.80 | MAP2K1 (0.61) | MAP2K1CNR2CAMKK2NEK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-1755597-A2 | AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007013896-A2 | PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007013896-A2 | PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060058340-A1 | Compounds modulating c-kit activity | PLEXXIKON INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | PLEXXIKON, INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2006009755-A2 | AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MAP2K1 746/4885CNR2 2545/4885CAMKK2 345/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MAP2K1 153/4885CNR2 2801/4885CAMKK2 100/4885 |
| US-20060058340-A1 | Compounds modulating c-kit activity | KIT, CDC7, CDK7 | MAP2K1 536/4885CNR2 3121/4885CAMKK2 534/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | MAP2K1 688/4885CNR2 2674/4885CAMKK2 349/4885 |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | KIT, APC, RET | MAP2K1 519/4885CNR2 2679/4885CAMKK2 569/4885 |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | KIT, FLT3, FLT1 | MAP2K1 774/4885CNR2 3286/4885CAMKK2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.